Autopsy report · NCT01998035

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

“PI left institution”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 6 years 2 months before it stopped.
• 58 participants enrolled.
• Results were posted on the registry 4 years 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Columbia University

Sponsor type

University, hospital or other

Conditions

Lymphoid Malignancies; Lymphoma; Hodgkin Lymphoma; Non-hodgkin Lymphoma

Interventions

RomiDEPsin 10 MG/M2; Oral 5-Azacitidine 100 MG; Romidepsin 14 MG/M2; Oral 5-Azacitidine 200 MG; Oral 5-Azacitidine 300 MG

Participants

58

Sites

1

Countries

United States

Trials that died the same way

• Oscillatory Versus Non-Oscillatory Nasal Continuous Airway Pressure Neonatal Respiratory Support
  “PI has left Institution” (96% match in meaning)
• Cilostazol After Lower Extremity Arterial Revascularization Trial
  “Original PI left institution” (94% match in meaning)
• Pediatric Pilot Study: Irrigation and Scrubbing in Facial and Scalp Wounds
  “PI left the institution” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.